S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:CRON

Cronos Group (CRON) Stock Price, News & Analysis

$2.30
+0.06 (+2.68%)
(As of 02/27/2024 ET)
Today's Range
$2.24
$2.31
50-Day Range
$1.86
$2.30
52-Week Range
$1.64
$2.64
Volume
2.09 million shs
Average Volume
2.28 million shs
Market Capitalization
$876.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Cronos Group MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
19.6% Upside
$2.75 Price Target
Short Interest
Healthy
3.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Cronos Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.08) to $0.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

764th out of 944 stocks

Medicinals & Botanicals Industry

8th out of 9 stocks


CRON stock logo

About Cronos Group Stock (NASDAQ:CRON)

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

CRON Stock Price History

CRON Stock News Headlines

Cronos Group (CRON) Set to Announce Earnings on Thursday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
3 Stocks Under $10 for 10-Bagger Returns by 2030
Cronos Group Inc. (NASDAQ:CRON) Short Interest Up 6.3% in January
CRON Mar 2024 3.000 call
CRON Jan 2025 5.500 put
Cronos Group Inc.: Cronos Enters Australian Cannabis Market
Jefferies Keeps Their Hold Rating on Cronos Group (CRON)
Week in DeFi: Ledger Compromised Again
3 Underperforming Cannabis Stocks You Better Not Be Buying
Cronos Group Inc.'s (TSE:CRON) Profit Outlook
See More Headlines
Receive CRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2021
Today
2/27/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CRON
Fax
N/A
Employees
447
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+19.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-168,730,000.00
Net Margins
-124.40%
Pretax Margin
-95.35%

Debt

Sales & Book Value

Annual Sales
$90.51 million
Book Value
$3.00 per share

Miscellaneous

Free Float
373,826,000
Market Cap
$876.99 million
Optionable
Optionable
Beta
1.14
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Michael Ryan Gorenstein J.D.Mr. Michael Ryan Gorenstein J.D. (Age 37)
    President, CEO & Chairman
    Comp: $3.94M
  • Mr. James Holm (Age 41)
    Chief Financial Officer
    Comp: $314.31k
  • Mr. Jeffrey David Jacobson (Age 38)
    Chief Growth Officer
    Comp: $730.12k
  • Ms. Anna Shlimak (Age 38)
    Senior Vice President of Corporate Affairs & Strategy
    Comp: $530.5k
  • Mr. James Andrew McGinness III (Age 45)
    VP, Controller & Principal Accounting Officer
  • Mr. Shayne J. Laidlaw
    Director of Investor Relations & Strategy
  • Mr. Terry Gregory-Joseph Doucet (Age 34)
    General Counsel & Corporate Secretary
  • Ms. Shannon Buggy (Age 54)
    Senior VP & Global Head of People
    Comp: $438.81k
  • Mr. Arye Weigensberg (Age 41)
    Senior VP & Head of Research and Development














CRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Cronos Group stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRON shares.
View CRON analyst ratings
or view top-rated stocks.

What is Cronos Group's stock price target for 2024?

4 brokers have issued 1 year price objectives for Cronos Group's shares. Their CRON share price targets range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price.
View analysts price targets for CRON
or view top-rated stocks among Wall Street analysts.

How have CRON shares performed in 2024?

Cronos Group's stock was trading at $2.09 at the beginning of 2024. Since then, CRON shares have increased by 10.0% and is now trading at $2.30.
View the best growth stocks for 2024 here
.

When is Cronos Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our CRON earnings forecast
.

How can I listen to Cronos Group's earnings call?

Cronos Group will be holding an earnings conference call on Thursday, February 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) posted its earnings results on Thursday, August, 5th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.22. The firm had revenue of $15.60 million for the quarter, compared to the consensus estimate of $18.48 million. Cronos Group had a negative trailing twelve-month return on equity of 6.84% and a negative net margin of 124.40%. The business's quarterly revenue was up 57.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.31) EPS.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Tilray (TLRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and Organigram (OGI).

Who are Cronos Group's major shareholders?

Cronos Group's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.86%), Dimensional Fund Advisors LP (0.53%), Intact Investment Management Inc. (0.23%), Mirae Asset Global Investments Co. Ltd. (0.18%), AdvisorShares Investments LLC (0.13%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Jason Marc Adler and Michael Ryan Gorenstein.
View institutional ownership trends
.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRON) was last updated on 2/28/2024 by MarketBeat.com Staff